GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation.
We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. Our lead molecule, uproleselan, is currently in pivotal Phase 3 development for people with relapsed/refractory AML. In addition to this trial, uproleselan is being evaluated in a Phase 2/3 trial by the National Cancer Institute (NCI) as a potential new treatment for newly diagnosed AML patients fit for chemotherapy. Uproleselan is an investigational first-in-class, E-selectin antagonist that has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Our portfolio of investigational drugs also includes GMI-1687, which is in development for people living with sickle cell disease.
We are led by a management team with deep experience in the research, development, and commercialization of therapies for blood cancers and hematologic diseases. GlycoMimetics is headquartered in Rockville, MD, in the BioHealth Capital Region.